Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement

@article{Macphee2002TacrolimusPP,
  title={Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement},
  author={I Macphee and Salim Fredericks and Tracy Tai and Petros Syrris and Nicholas D. Carter and Atholl Johnston and Lawrence Goldberg and David W Holt},
  journal={Transplantation},
  year={2002},
  volume={74},
  pages={1486-1489}
}
Background. There is marked heterogeneity in blood concentrations of tacrolimus following standard body-weight-based dosing. This is most apparent in black patients, who have a higher dose requirement when compared with other ethnic groups. Differences in intestinal P-glycoprotein and hepatic and intestinal cytochrome P4503A activity have been postulated as contributing to this problem. Methods. The dose-normalized blood concentrations of tacrolimus at 3 months after renal transplantation were… Expand
Influence of CYP3A5 polymorphism on tacrolimus blood concentrations in renal transplant patients
TLDR
CYP3A5 gene A6986G polymorphism is associated with tacrolimus pharmacokinetics and dose requirements and pharmacogenetic methods could be employed prospectively to help the dose selection and to individualize immunosuppressive therapy according to the result. Expand
Personalized tacrolimus doses determined by CYP3A5 genotype for induction and maintenance phases of kidney transplantation.
TLDR
Determination of the CYP3A5 genotype would be helpful in the design of adequate immunosuppressive treatment and in lowering toxicity by predicting the doses of tacrolimus required for the induction and maintenance phases in individual kidney transplant recipients. Expand
Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients
TLDR
Kidney transplant recipients with the CYP3A5 *1 allele required a higher daily tacrolimus dose compared with those with the cytochrome P450 3A5*3/*3 genotype to maintain both the target trough level and AUC0–12, suggesting that this polymorphism is useful for determining the appropriate dose of tacolimus. Expand
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12
TLDR
Determination of CYP3A5 genotype is predictive of the dose of tacrolimus in renal transplant recipients and may help to determine the initial daily dose needed by individual patients for adequate immunosuppression without excess nephrotoxicity. Expand
Tacrolimus dosing in Chinese renal transplant patients is related to MDR1 gene C3435T polymorphisms.
TLDR
The results showed a significant association between tacrolimus levels per dose mg/kg/d and MDR1 gene C3435T polymorphism (P < .05), and the CC patients displayed a lower tacolimus level per dose than CT/TT patients. Expand
Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients.
TLDR
Genotype monitoring of the MDR1 gene reliably predicts the optimal dose of tacrolimus in renal transplant recipients and may predict the initial daily dose needed by individual patients to obtain adequate immunosuppression. Expand
The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients.
TLDR
The identification of patients with *1*1* 1*1 by CYP3A5 and CYP 3AP1 genotyping may have a clinically significant and positive impact on patient outcome with reduced rejection rate by providing pretransplant pharmacogenetic information for optimization of cyclosporine A dosing. Expand
Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients.
TLDR
The CYP3A5*3 polymorphism may be an important factor in determining the dose requirement for tacrolimus and genotyping can help determine the initial daily dose required by individual patients for adequate immunosuppression. Expand
Impact of Cytochrome P450 (CYP) 3A5 Genetic Polymorphism on Tacrolimus Doses and Concentration/Dose Ratio in Renal Transplant Recipients. Transplantation 2003; 76: 1233
The aim of any drug dosing regimen is to achieve and maintain therapeutic drug concentrations as rapidly as possible. For immunosuppression in solid organ transplantation, this is particularlyExpand
The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function
TLDR
Prospective trials are needed to prove that a genetic approach to Tc pharmacokinetics and its related side effects during the early period after grafting may improve patient outcome. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 16 REFERENCES
No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients.
TLDR
The findings suggest that the MDR-1 C3435T mutation and the CYP3A4-V variant are not major determinants of CsA efficacy in renal transplant recipients. Expand
MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity.
TLDR
The high frequency of the C allele in the African group implies overexpression of PGP and may have important therapeutic and prognostic implications for use of P GP dependent drugs in individuals of African origin. Expand
Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.
TLDR
A significant correlation of a polymorphism in exon 26 (C3435T) of MDR-1 with expression levels and function is observed and this polymorphism is expected to affect the absorption and tissue concentrations of numerous other substrates of M DR-1. Expand
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
TLDR
CYP3A5 was more frequently expressed in livers of African Americans than in those of Caucasians, and may be the most important genetic contributor to interindividual and interracial differences in CYP3A-dependent drug clearance and in responses to many medicines. Expand
Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study
TLDR
The polymorphism MDR1 3435 C/T predicts immune recovery after initiation of antiretroviral treatment, which suggests that P-glycoprotein has an important role in admittance of antifiltration drugs to restricted compartments in vivo. Expand
Frequency of C3435T polymorphism of MDR1 gene in African people
TLDR
Concentration of P-glycoprotein in intestinal epithelial cells and in a subset of lymphoid cells is substantially lower in people with the T/T genotype than those with the C/C genotype. Expand
P‐glycoprotein and Drug Therapy in Organ Transplantation
TLDR
The objective of this review is to discuss the effects of P‐gp modulation on the pharmacokinetics and the pharmacodynamics of immunosuppressive agents such as cyclosporine, tacrolimus, sirolima, and corticosteroids. Expand
Cytochrome P-450 3A4: regulation and role in drug metabolism.
  • F. Guengerich
  • Biology, Medicine
  • Annual review of pharmacology and toxicology
  • 1999
TLDR
Several issues remain to be resolved regarding the catalytic activity of the P-450 3A4 protein, including rate-limiting steps and the need for cytochrome b5, divalent cations, and acidic phospholipid systems for optimal activity. Expand
Racial variation in dosage requirements of tacrolimus
TLDR
The message of the article is that there is a need for a standardised and widely accepted definition of white-coat hypertension, and it is repeated that outcome studies are required to resolve whether or not patients with white- coat hypertension require long-term treatment. Expand
Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living‐donor liver transplantation
TLDR
Whether the absorptive barriers, multidrug resistance protein (MDR1), or cytochrome P450 IIIA4 (CYP3A4) are important pharmacokinetic factors for tacrolimus and are prognostic indicators for LDLT outcome is examined. Expand
...
1
2
...